T3D Therapeutics is a clinical-stage biotechnology company focused on developing novel therapeutics for Alzheimer's disease and other neurodegenerative disorders. The company's lead program, T3D-959, is a first-in-class PPAR delta/gamma dual agonist that targets metabolic dysfunction in the brain, a key underlying contributor to Alzheimer's disease pathology[1].
Founded in 2013 and headquartered in Research Triangle Park, North Carolina, T3D Therapeutics takes a metabolic approach to treating Alzheimer's disease, targeting the brain's energy metabolism and insulin signaling pathways that become impaired in neurodegeneration.
| Program | Target/Mechanism | Indication | Phase | Status |
|---|---|---|---|---|
| T3D-959 | PPAR δ/γ dual agonist | Alzheimer's disease | Phase 2 | Active |
| T3D-231 | PPAR δ selective agonist | Parkinson's disease | Phase 1 | Completed |
| T3D-102 | Neuroinflammation modulator | Alzheimer's disease | Preclinical | Research |
T3D-959 is a first-in-class small molecule that activates both PPAR delta and PPAR gamma receptors, addressing metabolic dysfunction in the brain:
Metabolic Benefits:
Key Properties:
Phase 1 Studies:
Completed Phase 1 studies demonstrating:
Phase 2 Study (PIONEER):
The Phase 2 PIONEER study in patients with mild-to-moderate Alzheimer's disease is evaluating:
T3D Therapeutics targets brain metabolic dysfunction, which is increasingly recognized as a key contributor to Alzheimer's disease:
Key Findings:
Peroxisome proliferator-activated receptors (PPARs) are nuclear receptors that regulate metabolism:
PPAR Delta:
PPAR Gamma:
T3D-959's dual mechanism provides benefits:
Headquarters: Research Triangle Park, North Carolina, USA
Founded: 2013
Funding:
Leadership:
| Company | Program | Mechanism | Stage |
|---|---|---|---|
| T3D Therapeutics | T3D-959 | PPAR δ/γ agonist | Phase 2 |
| Eli Lilly | Donanemab | Anti-amyloid | Approved |
| Biogen/Eisai | Lecanemab | Anti-amyloid | Approved |
| Cognition/Novartis | CT1812 | Sigma-2 antagonist | Phase 2 |
| Lyterian | LYT-100 | NLRP3 inhibitor | Phase 1b/2a |